Pharmacology Researchers Develop a Novel Immunotherapy to Treat Malignancies

Pharmacology researchers develop a novel immunotherapy to treat malignancies.  In this therapy, T lymphocytes are harvested from patients with a malignancy and genetically modified to express a chimeric antigen receptor composed of an extracellular antigen recognition domain linked with an intracellular T-cell signaling domain.  These modified T cells are expanded ex vivo and then infused back into the patient, where they destroy the cancer cells.  In one of the experiments, they modify the chimeric antigen receptor to recognize CD19.  Use of this treatment is most likely to have which of the following potential complications?

A) Autoimmune endocrinopathy
B) Graft versus host disease
C) Hypogammaglobulinemia
D) Myelofibrosis
E) Prolonged myelosuppression

Correct Answer:

Verified

Unlock this answer now
Get Access to more Verified Answers free of charge

Access For Free